-+ 0.00%
-+ 0.00%
-+ 0.00%

IDEAYA Biosciences Completes Enrollment in Pivotal Phase 2/3 Trial of Darovasertib and Crizotinib for Metastatic Uveal Melanoma

Reuters·12/11/2025 11:00:57

Please log in to view news